U.S. markets closed
  • S&P Futures

    4,465.25
    +36.25 (+0.82%)
     
  • Dow Futures

    35,191.00
    +407.00 (+1.17%)
     
  • Nasdaq Futures

    15,144.25
    +107.00 (+0.71%)
     
  • Russell 2000 Futures

    2,264.10
    -8.00 (-0.35%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Silver

    23.35
    -0.13 (-0.54%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Vix

    16.30
    -0.56 (-3.32%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.54%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.46%)
     
  • BTC-USD

    60,874.29
    +87.47 (+0.14%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Vertex Inks Potential $1.2B Gene-Editing Pact With Arbor Biotechnologies

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Vertex Pharmaceuticals Inc (NASDAQ: VRTX) and Arbor Biotechnologies have announced a new collaboration to develop ex vivo engineered cell therapies.

  • The new agreement between Arbor and Vertex builds upon the companies' first partnership established in 2018.

  • Related: Intellia Shared Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate.

  • Under this new partnership, Vertex can use Arbor's proprietary CRISPR gene-editing technology to research and develop ex vivo engineered cell therapies.

  • The technology will go toward Vertex's insulin-producing hypoimmune islet cells to treat Type 1 diabetes and next-generation sickle cell disease and beta-thalassemia treatments.

  • The partnership includes up to seven potential programs.

  • Under the agreement terms, Arbor will receive an upfront cash payment and is eligible to receive up to $1.2 billion in potential milestone payments.

  • In addition, Vertex will pay tiered royalties on future net sales on any products that may result from this collaboration.

  • Vertex will also make an investment in Arbor in the form of a convertible note.

  • Price Action: VRTX shares are up 0.81% at $200 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.